Effect of ascorbic acid supplementation on plasma isoprostanes in haemodialysis patients.
Chan
Doris
D
Irish
Ashley
A
Croft
Kevin D
KD
Dogra
Gursharan
G
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D001205:Ascorbic Acid / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007262:Infusions, Intravenous; D028421:Isoprostanes / Q000097:blood*; D007676:Kidney Failure, Chronic / Q000175:diagnosis / Q000628:therapy*; D008297:Male; D008875:Middle Aged; D012016:Reference Values; D006435:Renal Dialysis / Q000009:adverse effects* / Q000379:methods; D018570:Risk Assessment; D012680:Sensitivity and Specificity; D012720:Severity of Illness Index; D016896:Treatment Outcome
D015415:Biomarkers; D028421:Isoprostanes; D001205:Ascorbic Acid